Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Texas Pathogen Panel Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - TexasPolicy RPLAB045

    Pathogen Panel Testing

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Texas Policy RPLAB045 alerts

    Get alerted when Policy RPLAB045 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This reimbursement policy governs payment criteria for pathogen panel testing performed in the outpatient setting. It affects providers submitting claims for respiratory and other pathogen panel tests, subject to the member's plan documents and provider contract.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPathogen Panel Testing
    Policy CodePolicy RPLAB045
    Change TypeModified
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionDo not expect reimbursement for molecular-based panel testing used to screen for or diagnose joint infections.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added a reimbursement rule stating that molecular-based panel testing to screen for or diagnose joint infections is not reimbursable.

    CPT code 87627 and proprietary code 0601U were added to the policy.

    Proprietary codes 0441U and 0442U were removed from the policy.

    The policy history documents revised respiratory panel reimbursement criteria based on symptoms, immunocompromised status, and panel size.

    The policy added respiratory and other laboratory testing codes during prior revisions, including 87428, 0202U, 0223U, 0225U, 0556U, 0563U, 0564U, 0590U, 0593U, 0600U, and 0610U.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Outpatient onlySetting
    Up to 5Symptomatic respiratory panels
    Up to 25Immunocompromised panels
    6+ pathogensBroad panels outside criteria
    Not reimbursableJoint-infection panels
    2 added / 2 removedLatest code changes

    Pathogen Panel Reimbursement Criteria

    Outpatient Scope, Modalities, and Specimen/Use Exclusions

    This policy is specific to pathogen panel testing performed in the outpatient setting. The criteria below do not apply to testing performed in any other setting.

    ALL of the following

    • Testing is performed in the outpatient setting.
    • The testing is not reimbursable when ANY of the following apply

      • Multiplex PCR-based panel testing of pathogens is performed in cerebral spinal fluid (CSF).
      • Molecular detection-based panel testing of pathogens is performed in the blood.
      • Molecular detection-based panel testing of urine pathogens is performed for diagnosis of a urinary tract infection, including tests such as the GENETWORx Molecular PCR UTI Test.
      • Molecular-based panel testing is used to screen for or diagnose a wound infection, including tests such as GENETWORx PCR Wound Testing.
      • Molecular-based panel testing is used for general screening of microorganisms, including tests such as MicroGenDX qPCR+NGS.

    Joint-Infection Molecular Panel Testing

    Molecular-based panel testing to screen for or diagnose joint infections is not reimbursable.

    Molecular-based panel testing to screen for or diagnose a joint infection is not reimbursable, including the BIOFIRE® Joint Infection (JI) Panel and Synovasure® Comprehensive PJI Test Panel with SynTuition™.

    Respiratory Pathogen Panel Testing

    For outpatient respiratory pathogen panel testing, reimbursement may be available only under the qualifying circumstances below. Testing involving six or more respiratory pathogens is not reimbursable when the circumstances described for the qualifying respiratory panels are not met.

    Apply the first applicable respiratory testing circumstance

    • Signs and symptoms with a panel of up to 5 pathogens

      • The individual is displaying signs and symptoms of a respiratory tract infection.
      • The panel includes up to 5 respiratory pathogens.<= 5 pathogens
      • Testing uses antigen panel testing or multiplex PCR-based panel testing.
    • Immunocompromised individual with a panel of up to 25 pathogens

    Applicable Codes and Panel Size Limits

    Listed CPT pathogen and respiratory panel proceduresCPT
    87154Culture, typing, identification of blood pathogen, 6 or more targets
    87428SARS-CoV and influenza virus A and B antigen testing
    87483Central nervous system DNA amplification probe, 12-25 targets
    87627Joint specimen pathogen and resistance gene testing, 26 or more targets
    87631Respiratory virus testing, 3-5 targets
    87632Respiratory virus testing, 6-11 targets
    87633Respiratory virus testing, 12-25 targets
    87636SARS-CoV-2 and influenza A and B amplification probe
    87637SARS-CoV-2, influenza A and B, and RSV amplification probe
    87812SARS-CoV-2 and influenza A and B antigen testing with optical detection
    Listed proprietary laboratory pathogen testing proceduresCPT
    0068UCandida species panel amplification probe
    0086UInfectious disease bacterial and fungal organism identification, 6 or more targets
    0109UAspergillus DNA identification, 4 species
    0112UInfectious agent identification using 16S and 18S rRNA genes
    0115URespiratory infectious agent DNA identification, 18 viral and 2 bacterial targets
    0140UFungal infectious disease DNA testing, 15 targets
    0141UBacterial and fungal infectious disease testing, gram-positive organisms
    0142UBacterial and fungal infectious disease testing, gram-negative organisms
    0152UInfectious disease DNA testing by untargeted non-genomic sequencing
    0202UInfectious disease testing, 22 targets including SARS-CoV-2
    1–10 of 28
    1/3
    Codes added in the latest revisionmixed
    87627Joint specimen pathogen and resistance gene testing, 26 or more targets
    0601UPeriprosthetic joint infection analysis, 11 biomarkers
    Codes removed in the latest revisionmixed
    0441U
    0442U
    Codes added in the January 2026 revisionmixed
    87428SARS-CoV and influenza virus A and B antigen testing
    0202UInfectious disease testing, 22 targets including SARS-CoV-2
    0223UInfectious disease testing, 22 targets including SARS-CoV-2
    0225UInfectious disease DNA and RNA testing, 21 targets including SARS-CoV-2
    0556UInfectious disease pathogen DNA and RNA testing, 12 targets
    0563UPathogen testing from synovial or other specimen, 11 viral and 4 bacterial targets
    0564UPathogen testing from synovial or other specimen, 10 viral and 4 bacterial targets
    Codes removed in the January 2026 revisionmixed
    0240U
    0241U
    0370U
    0373U
    0374U
    Codes added in prior 2026 revisionsmixed
    0590UBacterial and fungal infectious disease DNA testing, 44 organisms
    0593UGenitourinary pathogen DNA testing, 46 targets
    0600UWound infection infectious disease testing, 65 organisms and 30 additional targets
    0610UAntimicrobial susceptibility testing by phenotypic method
    Codes removed in prior 2025 revisionsmixed
    0151U
    0408U
    0416U
    0531UInfectious disease testing for acid-fast bacteria and invasive fungi, 673 organisms
    Symptomatic Respiratory Panel Limit
    Standard symptomatic panelUp to 5 respiratory pathogens; antigen or multiplex PCR-based panel testing may be reimbursable.
    Applicable clinical situationIndividual is displaying signs and symptoms of a respiratory tract infection.
    Testing modalitiesAntigen panel testing or multiplex PCR-based panel testing.
    Immunocompromised Symptomatic Respiratory Panel Limit
    Immunocompromised panelUp to 25 respiratory pathogens by multiplex PCR-based panel testing may be reimbursable.

    Billing, Documentation, and Submission Guidance

    Documentation Required

    Submit Accurate Claim Documentation and Coding

    Submit accurate documentation of the services performed and use valid HIPAA-approved code combinations. Code claims in accordance with applicable industry standards, including CPT, HCPCS, ICD-10-CM/PCS, NDC, CMS, and other relevant coding guidelines.

    • Use valid code combinations and applicable coding edits.
    • Follow industry-standard coding guidance, including CMS National Correct Coding Initiative policies and CCI table edits.
    Billing Rule

    Account for Claim Review and Code Edits

    Claims are subject to code-edit protocols and claim review. Reimbursement may also be affected by benefit terms, provider contracts, medical policies, reimbursement policies, and coding software logic.

    Terminology and Scope

    Outpatient Setting
    Applicable settingTesting performed in the outpatient setting.
    Other settingsThe stated criteria do not apply to testing in other than the outpatient setting.
    Scope of criteriaThe setting limitation applies to the pathogen panel reimbursement criteria.
    Signs and Symptoms of Respiratory Tract Infection
    General signs and symptomsFever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia, headaches, myalgia, diarrhea, and weakness.
    Additional pediatric signsIrritability, decreased activity, nausea, rash, stomach pain, ear tugging or otalgia, vomiting after coughing, tachypnea, chest retractions or nasal flaring, grunting, wheezing, crackles, dehydration, cyanosis, apnea episodes, drooling, or refusal to eat.
    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPathogen Panel Testing
    Policy CodePolicy RPLAB045
    Change TypeModified
    Effective DateDec 4, 202615d
    Next Review DateN/A
    Key ActionDo not expect reimbursement for molecular-based panel testing used to screen for or diagnose joint infections.
    SourceLink
    On This Page
    Pathogen Panel Reimbursement CriteriaApplicable Codes and Panel Size LimitsBilling, Documentation, and Submission GuidanceTerminology and Scope
    The individual is immunocompromised.
  1. The individual is displaying signs and symptoms of a respiratory tract infection.
  2. Testing uses multiplex PCR-based panel testing.
  3. The panel includes up to 25 respiratory pathogens.<= 25 pathogens
  4. For all situations not described above, antigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable.>= 6 pathogens
  5. Respiratory tract infection signs and symptoms may include

    • Adults and individuals of any age: fever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia, headaches, myalgia, diarrhea, or weakness.
    • Individuals younger than 18 years: irritability, decreased activity, nausea, rash, stomach pain, ear tugging or otalgia, vomiting after coughing, tachypnea, chest retractions or nasal flaring, grunting, wheezing, crackles, dehydration, cyanosis, apnea episodes, drooling, or refusal to eat.
    • Infants: nonspecific signs such as poor feeding, lethargy, or fussiness may occur instead of clear localizing symptoms.
    Applicable clinical situationIndividual is immunocompromised and displaying signs and symptoms of a respiratory tract infection.
    Testing modalityMultiplex PCR-based panel testing.
    Broad Respiratory Panel Exclusion Threshold
    Exclusion threshold6 or more respiratory pathogens.
    Testing modalitiesAntigen panel testing or multiplex PCR-based panel testing.
    Qualifying exceptionThe exclusion applies to situations not described under the symptomatic or immunocompromised symptomatic criteria.
    Standard Symptomatic Respiratory Panel Size
    Panel sizeUp to 5 respiratory pathogens.
    Required clinical contextIndividual has signs and symptoms of a respiratory tract infection.
    Potentially reimbursable modalitiesMultiplex PCR-based or antigen panel testing.
    Immunocompromised Symptomatic Respiratory Panel Size
    Panel sizeUp to 25 respiratory pathogens.
    Required clinical contextIndividual is immunocompromised and has signs and symptoms of a respiratory tract infection.
    Potentially reimbursable modalityMultiplex PCR-based panel testing.
    Respiratory Panel Size Outside Specified Criteria
    Nonreimbursable panel size6 or more respiratory pathogens.
    Applicable situationsSituations outside the specified respiratory testing criteria.
    Affected modalitiesAntigen panel testing or multiplex PCR-based panel testing.
    • Review applicable coding rules and claim edits before submission.
    • Benefit coverage and contract terms may govern reimbursement.
    Documentation Required

    Provide Records Upon Request

    Submit additional documentation or medical records when requested to support the services billed.

    Billing Rule

    Verify Product-Specific Coverage

    Review the applicable Plan documents before submitting services because reimbursement requirements may vary by product. Plan documents and provider contracts govern if they conflict with this reimbursement policy.

    • Check Certificates of Health Care Benefits, Benefit Booklets, Summary Plan Descriptions, and other applicable coverage documents.
    Billing Rule

    Confirm Outpatient Setting

    Apply the pathogen panel criteria only to testing performed in the outpatient setting. These criteria do not apply to testing performed in other settings.

    Billing Rule

    Respiratory Panel Up to 5 Pathogens

    For individuals displaying signs and symptoms of a respiratory tract infection, submit qualifying antigen panel testing or multiplex PCR-based panel testing for up to 5 respiratory pathogens when reimbursement criteria are met.

    • Applies to symptomatic individuals.
    • Qualifying methods include antigen panel testing and multiplex PCR-based panel testing.
    Billing Rule

    Immunocompromised Respiratory Panel Up to 25 Pathogens

    For immunocompromised individuals displaying signs and symptoms of a respiratory tract infection, submit qualifying multiplex PCR-based panel testing for up to 25 respiratory pathogens when reimbursement criteria are met.

    • Document both the immunocompromised status and respiratory symptoms.
    Denial Risk

    Avoid Nonreimbursable Broad Respiratory Panels

    Do not submit antigen or multiplex PCR-based respiratory panels testing for 6 or more pathogens unless the submission meets the specified qualifying situation for symptomatic individuals or symptomatic immunocompromised individuals.

    • Panels of 6 or more respiratory pathogens are not reimbursable outside the specified criteria.
    Denial Risk

    Avoid Excluded Specimen and Screening Panels

    Do not submit excluded molecular or multiplex pathogen panels involving cerebral spinal fluid, blood, urine for urinary tract infection diagnosis, wounds, or general microorganism screening.

    • Urine UTI example: GENETWORx Molecular PCR UTI Test.
    • Wound example: GENETWORx PCR Wound Testing.
    • General microorganism screening example: MicroGenDX qPCR+NGS.
    Documentation Required

    Document Respiratory Symptoms

    Document the signs and symptoms supporting the applicable respiratory panel criterion. Respiratory infection symptoms may include fever, chills, fatigue, cough, rhinorrhea, pharyngitis, vomiting, headache, myalgia, diarrhea, weakness, and age-specific pediatric or infant findings.

    • For patients younger than 18, consider documented findings such as irritability, tachypnea, wheezing, dehydration, cyanosis, apnea, or refusal to eat.
    • For infants, poor feeding, lethargy, and fussiness may be nonspecific respiratory infection signs.
    Denial Risk

    Joint-Infection Molecular Panels Are Not Reimbursable

    Do not submit molecular-based panel testing to screen for or diagnose joint infections; these services are not reimbursable under this policy.

    • Examples include the BIOFIRE Joint Infection (JI) Panel.
    • Synovasure Comprehensive PJI Test Panel with SynTuition is also an example.
    Infant presentationsPoor feeding, lethargy, or fussiness may present over clear localizing symptoms.
    Qualifying Clinical Context
    Standard qualifying contextThe individual has signs and symptoms of a respiratory tract infection.
    Expanded qualifying contextThe individual is immunocompromised and has signs and symptoms of a respiratory tract infection.
    Context outside the criteriaFor situations not described above, testing of 6 or more respiratory pathogens is not reimbursable.